

INVESTOR NEWS



June 2023

2CUREX HAS STRONG PRESENCE AT THE ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER



2cureX Booth at ESMO GI

When the premier global congress in gastrointestinal cancer (ESMO GI) starts on 28. June 2023 in Barcelona, 2cureX will be ready to meet current and future customers at our newly designed Booth and to present at scientific displays.

ESMO GI is bringing together clinicians, researchers, and professionals from around the world to present and discuss new clinical findings and technologies to tackle some of the most devastating cancers we have. It is an exceptional venue to present clinical benefits of the IndiTreat products.

[Read about ESMO GI here](#)

CEO BLOG: OUR COLORECTAL CANCER PORTFOLIO IS ON TRACK – PANCREAS CANCER IS NEXT

2cureX colorectal cancer portfolio development was defined as an upstream pathway through the patient journey, starting from the very late stages of the disease (3rd line treatment of Stage IV patients – IndiTreat Extend and IndiTreat Explore), moving to 1st line treatment of Stage IV patients (IndiTreat Start) and soon, to Stage III and Stage II patients (IndiTreat Neo).

With these four products, we will be covering more than 90% of the “drug choice” situations oncologists face in colorectal cancer (more than 2 million decisions are being made every year for CRC patients). So, as we work on the commercial rollout of those, the valid question from our development team is **“what’s next?”**.



CEO Fernando Andreu

Building on existing knowledge and partnerships – presenting at ESMO GI 2023

2cureX history with pancreatic cancer goes back to 2019, when the first feasibility tests were conducted, showing that the IndiTreat base technology could be applied to this type of tumor. Since then, and together with our clinical partner Universitätsklinikum Hamburg-Eppendorf (UKE), we have been advancing the understanding of patient’s responses to treatments and taking the preliminary steps to develop a CE-Marked IVD test.

[Read the full Blog here](#)



In the first week of June Jesper F. Kristensen (2cureX) and Lennart Bønnelykke (2cureX) met with distributors in Israel.

EXPANSION OF 2CUREX’S SALES TEAM

On 1. June, we expanded our Sales Team with Lennart Bønnelykke. Lennart has a strong background in Sales and Management positions in the In-vitro Diagnostics (IVD) industry in both direct market and export environment. He has developed markets and grown profitable sales in Europe, Middle East and Asia for primarily small to mid-sized IVD companies.

Early in his career Lennart had more than 10 years’ experience as a Laboratory Manager in Department of Pathology at a major University hospital.

Upcoming events in Q2 2023:

- 28. June – 1. July 2023 – 2cureX present at ESMO World Congress on Gastrointestinal cancer ([link to ESMO GI](#))
- 12. July 2023 – 2cureX Webcast – Get the latest news from the second quarter of 2023 and Q&A ([link to Webcast](#))
- 15. July 2023 – CEO Blog: IVD-R and 2cureX Newsletter
- 24. August 2023 – Release of Q2 2023 report
- 25. August 2023 – Q2 2023 live commentary at Infront Direkt Studios

Contact

ADDRESS

2cureX
Fruebjergvej 3,
2100 Copenhagen,
Denmark

E-MAIL (INVESTORS)

ir@2curex.com

E-MAIL (OTHER QUESTIONS)

info@2curex.com

